Eli Lilly's new diabetes treatment Jardiance stole market share from its rivals. The increased market share of 25 percent of new U.S. patients was attributed to clinical trial data showing fewer deaths among type 2 diabetics by 32 percent.
Eli Lilly's Jardiance Diabetes Treatment Steals Market Share From Rival Drugs
Tech Times - 7 Jan 2016 14:43
Eli Lilly's new diabetes treatment Jardiance stole market share from its rivals. The increased market share of 25 percent of new U.S. patients was attributed to clinical trial data showing fewer deaths among type 2 diabetics by 32 percent.
Share this Article
Recommended